A detailed history of Corbenic Partners LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Corbenic Partners LLC holds 20 shares of CRSP stock, worth $818. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20
Previous 60 66.67%
Holding current value
$818
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 25, 2022

SELL
$43.23 - $73.83 $1,729 - $2,953
-40 Reduced 66.67%
20 $1,000
Q1 2022

Apr 14, 2022

SELL
$53.19 - $79.24 $35,105 - $52,298
-660 Reduced 91.67%
60 $4,000
Q4 2021

Jan 21, 2022

SELL
$70.09 - $111.29 $3,154 - $5,008
-45 Reduced 5.88%
720 $55,000
Q1 2021

Apr 14, 2021

BUY
$110.72 - $210.04 $84,700 - $160,680
765 New
765 $93,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.19B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Corbenic Partners LLC Portfolio

Follow Corbenic Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corbenic Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corbenic Partners LLC with notifications on news.